MedImmune and Infinity : Preclinical Data Highlighting Potential of Retaspimycin in Treating Non-Small Cell Lung Cancer With Acquired Drug Resistance

April 15, 2008 – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and MedImmune announced that preclinical studies evaluating lead drug candidate retaspimycin hydrochloride ("retaspimycin," also known as IPI-504) suggest that retaspimycin represents a novel strategy for the potential treatment of patients with non-small cell lung cancer (NSCLC) who exhibit resistance to Iressa® (gefitinib) or Tarceva® (erlotinib). Data were presented today during the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California. Retaspimycin, a selective small molecule inhibitor of heat shock protein 90 (Hsp90), is currently being evaluated in the Phase 2 portion of an ongoing Phase 1/2 clinical trial in patients with advanced non-small cell lung cancer... MedImmune's Press Release - Infinity's Press Release -